CD8 Immunohistochemistry (IHC) Test in UAE | 450 AED | 2026 DHA Guidelines

A: The CD8 IHC test measures the density and distribution of CD8-positive cytotoxic T lymphocytes within your tumor tissue — these are the immune cells that directly attack and destroy cancer cells, making their presence a powerful predictor of immunotherapy response and overall survival outcomes. The test uses monoclonal antibodies that specifically bind to the CD8 protein on T-cell surfaces, allowing pathologists to visualize and count these immune defenders under a microscope. A high CD8+ T-cell infiltration pattern often correlates with better prognosis and enhanced responsiveness to immune checkpoint inhibitors. Your oncologist uses this data to stratify risk, personalize your treatment plan, and decide whether immunotherapy is likely to benefit you.

A: For tissue-based CD8 IHC testing, no personal preparation is needed — the test is performed on a tumor biopsy specimen already collected by your surgeon or interventional radiologist, which must be submitted as a formalin-fixed paraffin-embedded block or in 10% formal-saline solution. Our premium home collection service (8 AM to 11 PM daily) can retrieve your FFPE block or tissue sample from your location using ISO-certified cold-chain transport protocols, ensuring specimen integrity from pickup to laboratory processing. You must provide a copy of your histopathology report, biopsy site documentation, and complete clinical history at the time of submission — without these, accurate IHC interpretation cannot be guaranteed.

A: Our CD8 IHC test delivers 99.9% diagnostic sensitivity through ISO 9001:2015 accredited processing and digital pathology validation, providing your oncology team with a spatially-resolved map of immune cell infiltration that directly informs immunotherapy eligibility, prognosis, and clinical trial qualification. Results are reported as the percentage of CD8+ cells per high-power field along with distribution pattern analysis — intratumoral, peritumoral, or stromal. High CD8 infiltration typically supports immunotherapy candidacy, while low levels may prompt alternative strategies. All results include complimentary telephonic clinical guidance from our DHA-licensed specialists to ensure you and your physician fully understand the implications before any treatment change is made.